SALMETEROL XINAFOATE
Salmeterol xinafoate is a long-acting 2-agonist providing bronchodilation for asthma and COPD. It relaxes airway smooth muscle via cyclic AMP elevation. Side effects include tremor, tachycardia, headache, throat irritation, and rare paradoxical bronchospasm. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
SALMETEROL XINAFOATE displays a multidimensional biochemical activity profile integrating modulation of enzymatic pathways, receptormediated signalling, mitochondrial bioenergetics, oxidativestress homeostasis, ionchannel dynamics, membrane structural behaviour and transcriptionfactor regulation. Structural modelling suggests interactions with catalytic residues, allosteric microdomains, transmembrane helices, signalling cofactors and cytoskeletal complexes. These interactions enable influence over phosphorylation cascades, secondmessenger flux (Ca²⁺, IP, DAG, cAMP), ROS balance, ATP turnover, membranepotential stability and organelle stressresponse thresholds.
Benefits and Applications
- Receptorligand affinity analysis and docking studies
- Enzymekinetic profiling and catalyticflux pathway mapping
- Mitochondrialfunction modelling and ATP/ROS system evaluation
- Transcriptomic, metabolomic, proteomic and phosphoproteomic profiling
- Cytoskeletalarchitecture and membranedynamics exploration
- Apoptosis, autophagy, necroptosis and ferroptosis pathway modelling
- SAR/QSAR modelling and compoundoptimisation workflows
- Mechanistic pharmacodynamics and doseresponse simulation
Side Effects and Risks
- Oxidativestress imbalance and elevated ROS
- Mitochondrial overload or respiratorychain suppression
- Disruption of Ca²⁺/Na⁺/K⁺ ionhomeostasis
- Unintended receptor crosstalk or inhibitory signal interference
- Cytoskeletal destabilisation and membrane-integrity reduction
- Dosedependent cytotoxicity or programmed-cell-death activation
- Transcriptional and epigenetic instability
- Inflammatorycascade activation (NF-κB, MAPK, JNK)
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C25H37NO4Br·(C11H10O4)2 |
|---|---|
| Molecular Weight | 603.7 g/mol |
| CAS Number | 94749-08-3 |
| Storage Condition | The commercially available inhalation powder and inhalation device (Serevent Diskus) should be stored at room temperature (20-25 °C) in a dry place away from direct heat and sunlight. |
| Solubility | Sparingly soluble |
| Purity | Purity information is available upon request (COA). |
| Synonym | salmeterol xinafoate; 94749-08-3; Serevent diskus; Salmeterol 1-hydroxy-2-naphthoate; GR 33343 G |
| IUPAC/Chemical Name | 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid |
| InChl Key | XTZNCVSCVHTPAI-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
